



THE JOURNAL OF CLINICAL PSYCHIATRY

Supplementary Material

Article Title: The Vasopressin V_{1b} Receptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized Double-Blind, Placebo-Controlled Studies

Author(s): Guy Griebel, PhD; Sandra Beeské, MS; and Stephen M. Stahl, MD

DOI Number: 10.4088/JCP.12m07804

List of Supplementary Material for the article

1. [eAppendix 1](#) Complete list of study investigators

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eAppendix 1

Acknowledgments: The authors thank all the investigators who participated in these clinical trials: Boris Andreev, MD, St Petersburg City Mental Hospital, St Petersburg, Russia; Lisa Arvanitis, MD, former employee of Sanofi, Great Valley, Pennsylvania; Mohammed Abdul Bari, MD, Synergy Clinical Research Center, National City, California; Mikhael A. Burdokovsky, MD, Psychiatric Hospital, St Petersburg, Russia; John S. Carman, MD, Carman Research, Smyrna, Georgia; G. Michael Dempsey, MD, Albuquerque Neurosciences, Inc, New Mexico; Caroline M. DuPont, MD, DuPont Clinical Research, Inc, Rockville, Maryland; Beal Essink, MD, Oregon Center for Clinical Investigations, Inc, Portland, Oregon; Gary Gerard, MD, Neurology & Neuroscience Center of Ohio, Toledo, Ohio; Lev G. Gertsik, MD, California Clinical Trials Medical Group, Glendale, California; John H. Gilliam, MD, International Clinical Research Associates, LLC, Richmond, Virginia; Lawrence D. Ginsberg, MD, Red Oak Psychiatry Associates, PA, Houston, Texas; Alexander V. Golubey, Department of Psychiatry and Narcolepsy, St Petersburg, Russia; Ramanath Gopalan, MD, Comprehensive NeuroScience of Northern Virginia, Arlington, Virginia; James Grimm, MD, Oregon Center for Clinical Investigations, Inc, Eugene, Oregon; Andrew Hall, MD, St Boniface General Hospital, Winnipeg, Manitoba, Canada; Howard A. Hassman, DO, CRI Worldwide, LLC, Clementon, New Jersey; Carl Houck, University of Alabama at Birmingham, Birmingham, Alabama; Alan Jonas, MD, Pharmasite Research, Inc, Baltimore, Maryland; Arifulla Khan, MD, Northwest Clinical Research Center, Bellevue, Washington; Eva Kohegyi, MD, former employee of Sanofi, Great Valley, Pennsylvania; Victor A. Kontsevoy, MD, Mental Health Research Center of Russia, Moscow, Russia; Paul Latimer, MD, Okanagan Clinical Trials, Kelowna, British Columbia, Canada; Mrs Christiane L'Heritier, Sanofi, Chilly-Mazarin, France; Robert E. Litman, MD, CBH Health, LLC, Rockville, Maryland; Raymond Matte, MD, Q&T Research, Inc, Sherbrooke, Québec,

Canada; Alexander McIntyre, MD, Penticton, British Columbia, Canada; Charles Meredith, MD, Affiliated Research Institute, San Diego, California; Mrs Virginie Meunier, Paul R. Miller, MD, Pacific Clinical Research Medical Group, Pasadena, California; Margarita Nunez, MD, Comprehensive Neuroscience, St Petersburg, Florida; Jorg Pahl, MD, Pahl Pharmaceutical Research, LLC, Oklahoma City, Oklahoma; Angela L. Pinheiro, MD, Summit Research Network, Inc, Farmington Hills, Michigan; Benjamin Prasad, MD, St Boniface General Hospital, Winnipeg, Manitoba, Canada; John Prater, DO, Gulfcoast Clinical Research Center, Fort Myers, Florida; Robert Reisenberg, MD, Atlanta Center for Medical Research, Atlanta, Georgia; Norman E. Rosenthal, Capital Clinical Research Associates, LLC, Rockville, Maryland; Murray H. Rosenthal, DO, California Clinical Trials, San Diego, California; Richard Saini, MD, Clinical Neuroscience Solutions, Inc, Orlando, Florida; Angelo Sambunaris, MD, Atlanta Institute of Medicine & Research, Atlanta, Georgia; Scott D. Segal, MD, Scientific Clinical Research, Inc, Miami, Florida; Charmaine I. Semeniuk, MD, California Clinical Trials, San Diego, California; Vladislav K. Shamrey, MD, Department of Psychiatry Military Medical Academy, St Petersburg, Russia; John P.D. Shemo, Psychiatric Alliance of The Blue Ridge, Charlottesville, Virginia; Rajinder Shiwach, MD, InSite Clinical Research, DeSoto, Texas; Jose M. Itzcovich Schuster, MD, Sherman Oaks, California; Mary Stedman, MD, Stedman Clinical Trials, LLC, Tampa, Florida; Vladimir A. Tochilov, MD, Psychiatric Hospital St Nikolay, St Petersburg, Russia; Marie Trad, MD, former employee of Sanofi, Chilly-Mazarin, France; Peter Turner, MD, Schizophrenia Mood & Anxiety Disorders Treatment Centre, Burlington, Ontario, Canada; Cherian Verghese, MD, Keystone Clinical Studies, LLC, Norristown, Pennsylvania; David Walling, PhD, Collaborative Neuroscience Network, Inc, Torrance, California.